Technology Roadmap and Oracle Partnership Strengthen Long-Term Thesis; Target Price Raised to USD 95

Overview

Quantinuum reported 2Q26 results, with revenue above market expectations, adjusted EBITDA slightly below expectations, and full-year revenue and bookings guidance. Bernstein believes near-term financial figures are not the core issue; the investment thesis mainly depends on whether the company can deliver Sol, with around 100 logical qubits, and Apollo, with several hundred logical qubits, on schedule. During the quarter, chip validation, architecture prototypes, fidelity improvements, and Oracle’s Helios order all strengthened the analyst’s confidence in the technology roadmap and commercialization progress.

Core views

First, the Sol chip has completed fabrication and entered laboratory testing, validation, and integration, and is expected to be available in the second half of 2027; Apollo design has been completed, progress has been made on prototypes of key subsystems, and the 2029 timeline remains unchanged. Second, a new quantum error correction code brings logical fidelity close to five nines, allowing flexible configuration between higher fidelity and more logical qubits, strengthening the potential for production-grade applications. Third, Oracle’s purchase of Helios and deep integration into OCI should help expand customer reach, lower the development threshold, and validate the production quality of Quantinuum hardware. Fourth, Nexus user institutions increased to 180, indicating continued expansion of the software ecosystem and enterprise adoption. Fifth, the company remains in a stage of high investment and substantial losses, but approximately USD 2.1 billion of cash after the IPO provides funding support for parallel R&D across multiple product generations and market expansion.

Analysis framework

The report assesses the company’s outlook by combining quarterly results versus consensus expectations, product technology roadmap milestones, quantum error correction and fidelity progress, Nexus ecosystem adoption, Oracle commercial cooperation, and long-term financial forecasts; valuation uses a forward enterprise value/sales multiple approach, deriving the target price through net cash and share count.

Methodology notes

• Relative valuationEnterprise value/forward sales multiple method

  Using revenue over the future 12 months one year from now as the valuation basis

  The report uses a forecast of USD 218 million in future 12-month revenue one year from now, applies a 115x enterprise value/forward sales multiple, then adds back net cash and divides by 279 million shares to arrive at a target price of USD 95 per share.

• Earnings analysisActual results versus consensus expectations

  Comparing revenue, adjusted EBITDA, and earnings metrics with market expectations

  2Q26 revenue was approximately USD 8 million, about 5.2% above consensus expectations; adjusted EBITDA was approximately negative USD 68.3 million, slightly below consensus expectations. The report also distinguishes one-off impacts such as IPO-triggered equity compensation.

• Technology roadmap assessmentMilestone de-risking analysis

  Assessing long-term execution capability based on the R&D and delivery milestones of Sol, Apollo, and subsequent Lumos

  Each product generation shares and extends core designs such as two-dimensional ion traps, and validation of the current generation can reduce engineering risk for the next generation; key focus areas are whether Sol can be delivered in 2027 and Apollo in 2029 as scheduled.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• QNT.US (QUANTINUUM INC)

  Core covered company

  Strengths

  Leading high-fidelity ion-trap technology, with an integrated technology stack spanning hardware, software, and industry applications; clear Sol and Apollo roadmap; Oracle order and growth in Nexus adoption validate commercial demand; ample cash reserves.

  Weaknesses

  Still in the early stage of commercialization, with small revenue scale, substantial R&D investment, high losses and cash burn, and limited details in financial disclosures on revenue mix, backlog, and performance obligations.

  Comparison

  Compared with some competitors that emphasize qubit count, Quantinuum places more emphasis on logical fidelity and production usability; however, its forward sales valuation multiple is significantly higher than that of mature software and cloud computing companies.

  Risks

  Product delays, engineering and manufacturing challenges, breakthroughs in alternative quantum technologies, acceleration by competitors, market size falling short of expectations, and slow conversion of orders.

• ORCL.US (ORACLE CORP)

  Strategic partner and Helios purchaser

  Strengths

  Deep integration of Helios with OCI compute, networking, storage, identity, and data services can expand cloud platform capabilities and reduce the complexity for customers using quantum computing.

  Weaknesses

  The cooperation is still in the deployment and preview stage, and actual customer adoption, revenue contribution, and the synergy between quantum and classical computing workloads remain to be validated.

  Comparison

  Local deployment of quantum hardware and deep integration into OCI may give Oracle functional differentiation versus traditional hyperscale cloud providers that offer only limited quantum services.

  Risks

  Deployment delays, customer demand below expectations, insufficient maturity of cloud quantum applications, and failure of OCI customers to form scaled usage.

Key data

• 2Q26 revenueUSD 7.998 millionUp 279% year over year and about 5.2% above consensus expectations of USD 7.600 million.
• 2Q26 adjusted EBITDA-USD 68.3 millionSlightly below consensus expectations of -USD 64.5 million.
• FY26 revenue guidanceUSD 28 million to USD 32 millionThe company expects FY27 revenue growth to exceed 100%.
• FY26 bookings guidanceAt least USD 120 millionIncluding deals such as Oracle signed after the quarter, year-to-date bookings have reached USD 81 million.
• Nexus user institutions180An increase of 30 from 150 at the time of IPO, with actual usage also increasing.
• Logical fidelityClose to 99.999%Improved from about 99.921% to near five nines with the help of a new quantum error correction code.
• Sol planSecond half of 2027The chip is undergoing testing, validation, and system integration in the laboratory.
• Apollo plan2029Design has been completed, and progress has been made in prototype development of key architecture subsystems.
• Quarter-end cash and equivalentsApproximately USD 2.1 billionAfter completion of the IPO, the company has a funding base to support parallel R&D of multiple generations of systems.
• Target priceUSD 95Raised from USD 94; implies potential upside of about 69% versus the USD 56.06 closing price.

Impact & implications

For investors, near-term focus areas still include high R&D spending, equity compensation expenses, and sustained losses, but the key determinant of medium- to long-term value is whether the product roadmap can be delivered. The on-schedule progress of Sol and Apollo, step-change improvement in fidelity, and Oracle’s purchase and cloud deployment reduce technology and commercialization uncertainty. If the company can convert bookings, Nexus usage, and cloud partnerships into revenue, the current high valuation may be supported by growth; if delivery is delayed or market adoption slows, valuation compression risk will be very significant.

Risks

• Sol or Apollo R&D, production, and delivery progress may be later than planned.
• Engineering issues in two-dimensional ion-trap scaling, quantum error correction, or manufacturing may be harder to resolve than expected.
• Breakthroughs in other quantum technology routes such as topological or semiconductor approaches could weaken Quantinuum’s leading position.
• Competitors may accelerate their technology roadmaps and capture the market first.
• The actual serviceable market for quantum computing may be smaller than industry expectations, or mature more slowly than expected.
• The cycle for converting orders and business pipeline into revenue may lengthen.
• The company’s continued high R&D and operating investment may cause losses and cash burn to exceed expectations.
• The current valuation is highly dependent on rapid forward growth, and growth falling short of expectations could trigger significant valuation compression.
• IPO-related equity compensation and one-time expenses increase near-term volatility in financial data.

What to watch

• Specific progress of Sol laboratory validation, system integration, and transition to production, and whether delivery in the second half of 2027 can be achieved.
• Validation progress of Apollo key subsystem prototypes and larger two-dimensional chips.
• Peer-reviewed papers on the new quantum error correction code, system deployment effects, and the repeatability of near-five-nines fidelity.
• Oracle Helios delivery, timing of OCI preview launch, customer usage, and subsequent revenue contribution.
• Nexus customer count, usage intensity, and real enterprise-grade application cases.
• Completion of FY26 revenue target of USD 28 million to USD 32 million and bookings target of at least USD 120 million.
• FY27 revenue growth expectation of more than 100%, and the pace of conversion from orders to revenue.
• Whether disclosures improve regarding revenue mix, backlog, remaining performance obligations, and current remaining performance obligations.
• Cash burn, non-GAAP gross margin, and the normalization process of IPO-related equity compensation expenses.